Evidence map›Paper›PMID 41392193›Full record

ArticleNPJ precision oncology2025

Divergent oncogenic signaling and immune microenvironment changes in low-grade serous ovarian cancer patients undergoing intraperitoneal chemotherapy.

Isaac Bishara, Patrick A Cosgrove, Sumana Majumdar, Colt A Egelston, Oscar Colunga Flores, Brad Nakamura, Nora Ruel, Paul H Frankel, Susan E Yost, Sue Chang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Isaac BisharaDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Patrick A CosgroveDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Sumana MajumdarDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Colt A EgelstonDepartment of Immuno-Oncology, City of Hope National Medical Center, Duarte, CA, USA.
Oscar Colunga FloresDepartment of Immuno-Oncology, City of Hope National Medical Center, Duarte, CA, USA.
Brad NakamuraDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Nora RuelDepartment of Computation and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA, USA.
Paul H FrankelDepartment of Computation and Quantitative Medicine, City of Hope National Medical Center, Duarte, CA, USA.
Susan E YostDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Sue ChangDepartment of Pathology, City of Hope National Medical Center, Duarte, CA, USA.
Alexander JungDepartment of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA, USA.
Mihaela CristeaRegeneron Pharmaceuticals, New York, NY, USA.
Mustafa RaoofDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Andrea H BildDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA. abild@coh.org.
Aritro NathDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA. anath@coh.org.
Thanh H DellingerDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA. tdellinger@coh.org.

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572NCI NIH HHS P30CA033572
6 · The paper itself

Abstract

Low-grade serous ovarian carcinoma (LGSOC) is a rare, treatment-resistant subtype of ovarian cancer characterized by peritoneal spread. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) delivers chemotherapy directly into the abdomen during serial laparoscopic surgeries, enabling repeated sampling of tumors for longitudinal analysis. Using single-nuclei RNA sequencing on 15 tumor samples across PIPAC cycles in two patients (a responder and a non-responder), we tracked molecular and cellular changes over time. Non-responder tumors showed upregulation of proliferation pathways (E2F, MYC, G2/M), KRAS signaling, epithelial-mesenchymal transition, and unfolded protein response, correlating with resistance. Responder tumors exhibited downregulation of proliferation and stress pathways but activated alternative survival mechanisms (PI3K, Wnt/β-catenin, Notch). Archetype analysis revealed dynamic shifts in metabolic and immune-related subpopulations in the responder tumors, while immunoprofiling showed greater immunosuppression in non-responder tumors. Despite the small cohort, these exploratory observations highlight tumor adaptation and underscore the need for multi-targeted therapies addressing proliferation, stress, survival, and immune evasion.

Identifiers

PMID41392193
PMCPMC12764849

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.